Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | Director | February 17, 2026 | February 19, 2026 |
| Gritstone bio, Inc.GRTS · Entity 80946 | Director | June 17, 2022 | June 22, 2022 |
| KINETA, INC./DEYMTX · Entity 77778 | Director | June 02, 2021 | June 04, 2021 |
| Metacrine, Inc.MTCR · Entity 115177 | Director | May 18, 2022 | September 06, 2022 |
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | Director | October 01, 2026 | October 02, 2026 |
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | Director | June 05, 2025 | June 09, 2025 |
| Tango Therapeutics, Inc.BCTG · Entity 1497 | Director | September 02, 2020 | September 03, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enliven Therapeutics, Inc.
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 22,647 |
Reported balance
After 2026-02-17 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-02-17 · Sale · Disposed 1,230 · Balance 22,647 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust"). F2: This transaction was executed in multiple trades at prices ranging from $25.765 to $26.6949. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3: The shares are held of record by the Heyman Daigle Trust. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 25,545 |
Reported balance
Holding disclosure · report date 2026-02-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 25,545 F4: The shares are held of record by RAHD Capital LLC, for which the Reporting Person serves as a managing member. |
| Common StockSEC Table I · non-derivative | Direct | 123,673 |
Reported balance
Holding disclosure · report date 2026-02-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 123,673 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust").
F2: This transaction was executed in multiple trades at prices ranging from $25.765 to $26.6949. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: The shares are held of record by the Heyman Daigle Trust.
F4: The shares are held of record by RAHD Capital LLC, for which the Reporting Person serves as a managing member.
Gritstone bio, Inc.
Report date June 17, 2022 · Filed June 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2032-06-16 | Direct | 19,000 |
Reported balance
After 2022-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-17 · Grant · Acquired 19,000 · Balance 19,000 F1: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date.
KINETA, INC./DE
Report date June 02, 2021 · Filed June 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.26 · Expires 2031-06-01 | Direct | 14,800 |
Reported balance
After 2021-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-02 · Grant · Acquired 14,800 · Balance 14,800 F1: The shares subject to the option shall vest in equal quarterly installments over three years following June 2, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in equal quarterly installments over three years following June 2, 2021.
Metacrine, Inc.
Report date May 18, 2022 · Filed September 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2032-05-17 | Direct | 16,500 |
Reported balance
After 2022-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-18 · Grant · Acquired 16,500 · Balance 16,500 F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders.
Oric Pharmaceuticals, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,300 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 3,500 · Balance 41,800 Row 2 · 2026-10-01 · Sale · Disposed 3,500 · Balance 38,300 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2: This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 203,472 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Sale · Disposed 3,200 · Balance 203,472 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2: This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2028-02-28 | Direct | 26,700 |
Reported balance
After 2026-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Disposed 3,500 · Balance 26,700 F4: The shares subject to the option are fully vested and immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
F2: This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
F4: The shares subject to the option are fully vested and immediately exercisable.
PMV Pharmaceuticals, Inc.
Report date June 05, 2025 · Filed June 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2035-06-05 | Direct | 33,500 |
Reported balance
After 2025-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 33,500 · Balance 33,500 F1: Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders.
Tango Therapeutics, Inc.
Report date September 02, 2020 · Filed September 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,600 |
Reported balance
Holding disclosure · report date 2020-09-02 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 40,600 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RayzeBio, Inc.
Report date February 26, 2024 · Filed February 27, 2024
Section 16 reporting ended · disclosed 2024-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-26 transaction · row 1
1 source rowRow 1 · 2024-02-26 · Disposition to issuer · Disposed 367,446 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2024 Filed Feb 21, 2024 00:32 UTC Amendment | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 29,205 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001415889-24-004490 · form4a-02212024_120255.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,205 Underlying: Common Stock · 29,205 shares Expires 2034-02-13 F1 · shares: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. F2 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. F1 · derivative.underlying_shares: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. F1 · balance_after: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. Read SEC document |
| January 30, 2024 Filed Feb 2, 2024 01:10 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,270 | $16.41 | $20,839.56 |
DisclosureSEC source: 0001415889-24-002220 · form4-02022024_010213.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,010 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.10 to $16.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 00:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 35 | $13.00 | $455.00 |
DisclosureSEC source: 0001209191-23-059715 · doc4.xml · nonDerivative · entry 4 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 29,216 F1 · kind: The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023. F2 · ownership.nature: The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 00:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 168 | $13.00 | $2,184.00 |
DisclosureSEC source: 0001209191-23-059715 · doc4.xml · nonDerivative · entry 3 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,280 F1 · kind: The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023. Read SEC document |
| December 21, 2023 Filed Dec 27, 2023 00:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 6 | $13.00 | $78.00 |
DisclosureSEC source: 0001209191-23-059715 · doc4.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 29,251 F1 · kind: The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023. F2 · ownership.nature: The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member. Read SEC document |
| December 21, 2023 Filed Dec 27, 2023 00:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 7 | $13.00 | $91.00 |
DisclosureSEC source: 0001209191-23-059715 · doc4.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 21:28 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,915 | $13.02 | $24,939.43 |
DisclosureSEC source: 0001209191-23-059431 · doc4.xml · nonDerivative · entry 3 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 29,257 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.00 to $13.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 21:28 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,110 | $13.02 | $27,472.62 |
DisclosureSEC source: 0001209191-23-059431 · doc4.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,455 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.00 to $13.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 21:28 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 255 | $13.00 | $3,315.00 |
DisclosureSEC source: 0001209191-23-059431 · doc4.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,565 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:54 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001209191-23-037394 · doc4.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:39 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 21,500 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001209191-23-036427 · doc4.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-06-07 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 8, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:54 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantEmployee Stock Option (right to buy) · Derivative | 20,657 | Not disclosed Strike: $2.48 | Not disclosed |
DisclosureSEC source: 0001209191-23-013522 · doc4.xml · derivative · entry 4 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,657 Underlying: Common Stock · 20,657 shares Expires 2032-08-12 F5 · price: In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent). F4 · derivative.exercise_date: The option is subject to an early exercise provision and the shares underlying the option vest in 48 equal monthly installments beginning on January 14, 2021. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:54 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantCommon Stock | 31,172 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-013522 · doc4.xml · nonDerivative · entry 3 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 31,172 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN." F3 · ownership.nature: The shares held of record by RAHD Capital LLC for which the reporting person serves as a managing member. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:54 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantCommon Stock | 37,407 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-013522 · doc4.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 37,407 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN." F2 · ownership.nature: The shares held of record by the Richard A. Heyman and Anne E. Daigle Trust, dated November 1, 2016 for which the reporting person serves as trustee. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:54 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantCommon Stock | 149,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-013522 · doc4.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,820 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN." Read SEC document |
| February 23, 2023 Filed Apr 7, 2023 00:19 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 34,458 | $0.00 Strike: $25.28 | $0.00 |
DisclosureSEC source: 0001209191-23-023666 · doc4.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,458 Underlying: Common Stock · 34,458 shares Expires 2033-02-23 F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 17, 2022 Filed Jun 18, 2022 00:22 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 53,700 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001209191-22-038200 · doc4.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,700 Underlying: Common Stock · 53,700 shares Expires 2032-06-16 F1 · derivative.exercise_date: (A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 21:32 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001567619-22-013257 · doc1.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:41 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0001209191-22-034620 · doc4.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2032-06-01 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 2, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 18, 2022 Filed Sep 6, 2022 23:23 UTC | Metacrine, Inc. MTCR · Entity 115177 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001209191-22-048881 · doc4.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2032-05-17 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 22:19 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 682 | $25.03 | $17,073.67 |
DisclosureSEC source: 0001209191-21-056461 · doc4.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 216,272 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC. F4 · price: Represents the weighted average share price of an aggregate total of 682 shares sold in the price range of $25.00 to $25.19 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 22:19 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 706 | $25.05 | $17,686.08 |
DisclosureSEC source: 0001209191-21-056461 · doc4.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 216,954 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC. F2 · price: Represents the weighted average share price of an aggregate total of 706 shares sold in the price range of $25.00 to $25.28 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 20:03 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 601 | $25.01 | $15,032.99 |
DisclosureSEC source: 0001209191-21-055871 · doc4.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 217,660 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC. F4 · price: Represents the weighted average share price of an aggregate total of 601 shares sold in the price range of $25.00 to $25.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:03 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 479 | $25.10 | $12,023.14 |
DisclosureSEC source: 0001209191-21-055871 · doc4.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 218,261 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC. F2 · price: Represents the weighted average share price of an aggregate total of 479 shares sold in the price range of $25.05 to $25.17 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:36 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 1,086 | $25.11 | $27,272.18 |
DisclosureSEC source: 0001209191-21-055295 · doc4.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 218,740 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC. F2 · price: Represents the weighted average share price of an aggregate total of 1,086 shares sold in the price range of $25.00 to $25.26 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| June 18, 2021 Filed Nov 19, 2021 21:57 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $9.86 | $0.00 |
DisclosureSEC source: 0001567619-21-020858 · doc1.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option will vest and become exercisable on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:46 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 16,625 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001209191-21-041743 · doc4.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,625 Underlying: Common Stock · 16,625 shares Expires 2031-06-15 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 16, 2022 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 16:05 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 14,800 | $0.00 Strike: $15.26 | $0.00 |
DisclosureSEC source: 0000899243-21-022013 · doc4.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,800 Underlying: Common Stock · 14,800 shares Expires 2031-06-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over three years following June 2, 2021. Read SEC document |
| June 02, 2021 Filed Jun 9, 2021 21:30 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 16,333 | $0.00 Strike: $32.29 | $0.00 |
DisclosureSEC source: 0001209191-21-039237 · doc4.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,333 Underlying: Common Stock · 16,333 shares Expires 2031-06-01 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 2, 2022 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 975 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · derivative · entry 15 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,951 Underlying: Common Stock · 975 shares Expires 2027-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: All of the shares subject to the option are vested and immediately exercisable. F8 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Scott Z. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's son and descendants. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 975 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · derivative · entry 14 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,951 Underlying: Common Stock · 975 shares Expires 2027-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: All of the shares subject to the option are vested and immediately exercisable. F5 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Julia E. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's daughter and descendants. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 1,950 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · derivative · entry 13 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,901 Underlying: Common Stock · 1,950 shares Expires 2027-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: All of the shares subject to the option are vested and immediately exercisable. F1 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Heyman Family 2020 Irrevocable Trust under agreement dated August 31, 2020 for the benefit of the Reporting Person's immediate family. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 2 | $34.67 | $69.34 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · nonDerivative · entry 12 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F8 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Scott Z. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's son and descendants. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 209 | $33.79 | $7,061.73 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · nonDerivative · entry 11 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.62 to $33.875, inclusive. F8 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Scott Z. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's son and descendants. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 764 | $32.15 | $24,563.13 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · nonDerivative · entry 10 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 211 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.815, inclusive. F8 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Scott Z. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's son and descendants. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 975 | $975.00 | $950,625.00 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · nonDerivative · entry 9 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Scott Z. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's son and descendants. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 2 | $34.67 | $69.34 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · nonDerivative · entry 8 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F5 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Julia E. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's daughter and descendants. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 230 | $33.75 | $7,761.70 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · nonDerivative · entry 7 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.62 to $33.875, inclusive. F5 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Julia E. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's daughter and descendants. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 743 | $32.16 | $23,896.22 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · nonDerivative · entry 6 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 232 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.02 to $32.46, inclusive. F5 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Julia E. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's daughter and descendants. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 975 | $2.95 | $2,876.25 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · nonDerivative · entry 5 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Julia E. Heyman 2016 Irrevocable Trust under agreement dated November 1, 2016 for the benefit of the Reporting Person's daughter and descendants. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 5 | $34.67 | $173.35 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · nonDerivative · entry 4 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F1 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Heyman Family 2020 Irrevocable Trust under agreement dated August 31, 2020 for the benefit of the Reporting Person's immediate family. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 553 | $33.61 | $18,586.61 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · nonDerivative · entry 3 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.055 to $33.875, inclusive. F1 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Heyman Family 2020 Irrevocable Trust under agreement dated August 31, 2020 for the benefit of the Reporting Person's immediate family. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 1,392 | $32.15 | $44,754.05 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 558 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.01 to $32.815, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (6), (7), (9) and (10) to this Form 4. F1 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Heyman Family 2020 Irrevocable Trust under agreement dated August 31, 2020 for the benefit of the Reporting Person's immediate family. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:11 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionCommon Stock | 1,950 | $2.95 | $5,752.50 |
DisclosureSEC source: 0001209191-21-037144 · doc4.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held of record by Paul L. Vogel as Trustee of the Heyman Family 2020 Irrevocable Trust under agreement dated August 31, 2020 for the benefit of the Reporting Person's immediate family. Read SEC document |
| May 24, 2021 Filed May 24, 2021 23:30 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 100 | $25.00 | $2,500.00 |
DisclosureSEC source: 0001209191-21-035525 · doc4.xml · nonDerivative · entry 3 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 219,826 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| May 24, 2021 Filed May 25, 2021 23:01 UTC | Metacrine, Inc. MTCR · Entity 115177 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001209191-21-035784 · doc4.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-05-23 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2022 annual meeting of stockholders. Read SEC document |
| May 21, 2021 Filed May 24, 2021 23:30 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 600 | $25.25 | $15,150.00 |
DisclosureSEC source: 0001209191-21-035525 · doc4.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 219,926 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC. F4 · price: Represents the weighted average share price of an aggregate total of 600 shares sold in the price range of $25.18 to $25.35 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| May 20, 2021 Filed May 24, 2021 23:30 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 700 | $25.08 | $17,558.03 |
DisclosureSEC source: 0001209191-21-035525 · doc4.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 220,526 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC. F2 · price: Represents the weighted average share price of an aggregate total of 700 shares sold in the price range of $25.00 to $25.12 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| May 18, 2021 Filed May 19, 2021 00:22 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 2,161 | $25.32 | $54,715.44 |
DisclosureSEC source: 0001209191-21-033817 · doc4.xml · nonDerivative · entry 3 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 221,226 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC. F5 · price: Represents the weighted average share price of an aggregate total of 2,161 shares sold in the price range of $25.00 to $25.92 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| May 17, 2021 Filed May 19, 2021 00:22 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 498 | $25.07 | $12,483.81 |
DisclosureSEC source: 0001209191-21-033817 · doc4.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 223,387 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC. F4 · price: Represents the weighted average share price of an aggregate total of 498 shares sold in the price range of $25.00 to $25.14 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.